{"id":2123,"date":"2025-08-27T12:10:05","date_gmt":"2025-08-27T12:10:05","guid":{"rendered":"http:\/\/www.youtubexyoutube.com\/?p=2123"},"modified":"2025-08-29T13:47:00","modified_gmt":"2025-08-29T13:47:00","slug":"sputnik-v-developer-sets-out-plan-for-breakthrough-hiv-vaccine","status":"publish","type":"post","link":"http:\/\/www.youtubexyoutube.com\/index.php\/2025\/08\/27\/sputnik-v-developer-sets-out-plan-for-breakthrough-hiv-vaccine\/","title":{"rendered":"Sputnik V developer sets out plan for breakthrough HIV vaccine"},"content":{"rendered":"
Russian scientists say a new shot that triggers an immune response could be ready in around two years<\/strong><\/p>\n A Russian vaccine against the human immunodeficiency virus (HIV) could be ready in about two years, according to the top epidemiologist from the renowned Gamaleya Center in Moscow, as cited by RIA Novosti.<\/p>\n The much-anticipated HIV vaccine is based on mRNA technology, the head of the institute\u2019s epidemiology department, Vladimir Gushchin, told RIA Novosti on Wednesday. Unlike traditional vaccines, mRNA-based\u00a0variants work by delivering genetic instructions that teach the body\u2019s cells to produce specific proteins and trigger an immune response, helping the body recognize and defend against the actual virus if encountered.<\/p>\n \u201cWe are currently at the stage of creating the first antigens that will generate a broadly neutralizing immune response. The success of the vaccine will depend on whether the immunogen we use can trigger a response capable of protecting against all variants,\u201d<\/em> Gushchin said. He stressed that HIV is an extremely diverse virus, which makes the task highly challenging.<\/p>\n The Gamaleya Center also developed Sputnik V, one of the world\u2019s first Covid-19 vaccines, rolled out in August 2020. The shot, showing up to 97.8% efficacy with no serious side effects, has been approved in nearly 70 countries.<\/p>\n The researcher added that while work on an HIV vaccine has been underway for years, the mRNA platform offers a major advantage by stimulating a significantly stronger immune response.<\/p>\n